June, 2025
June 2025
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
Stephen V Liu: The Phase 2b REZILIENT1 study of zipalertinib met its primary endpoint
Feb 4, 2025, 10:31

Stephen V Liu: The Phase 2b REZILIENT1 study of zipalertinib met its primary endpoint

Stephen V Liu, Associate Professor of Medicine at Georgetown University, Director of Thoracic Oncology and Head of Developmental Therapeutics at the Georgetown Lombardi Comprehensive Cancer Center, shared a post on X:

“The Phase 2b REZILIENT1 study of zipalertinib (CLN-081/TAS6417) met its primary endpoint of response rate in patients with EGFR exon 20 insertion mutation NSCLC.”